AstraZeneca (NASDAQ:AZN) plans to cap out-of-pocket costs for its inhaler medications at $35 per month following Congressional criticism of the company's pricing of the products in the US. The cap, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback